MedTrace Logo

Safety and Efficacy of ADS-5102 in Multiple Sclerosis Patients With Walking Impairment

NCT03436199 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 558

Last updated 2021-12-21

Study results available
· View outcomes & findings →

Summary

This study assessed the efficacy and safety of ADS-5102 (at daily doses of 137 mg or 274 mg) compared with placebo in MS patients with walking impairment.

Conditions

Interventions

DRUG

ADS-5102, 137 mg

Oral capsules

DRUG

ADS-5102, 274 mg

Oral capsules

OTHER

Placebo

Oral capsules

Sponsors & Collaborators

  • Adamas Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials Director · Adamas Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-29
Primary Completion
2019-12-10
Completion
2019-12-10
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03436199 on ClinicalTrials.gov